Articles tagged with Peptides
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
Researchers from Kobe University have designed a small mirror protein that disables amyloid-beta, a causal factor of Alzheimer's disease. The approach uses the principle of 'chirality' to bind to the protein, inhibiting its aggregation and potential for brain cell damage.
A meta-analysis of GLP-1 receptor agonist studies found potential safety signals for gastrointestinal side effects, while some evidence suggested a link to reduced respiratory disease risk. Further research is needed to confirm the latter association.
A post hoc analysis found that tirzepatide was associated with a lower incidence of a broad composite cardiovascular and kidney endpoint. The study compared tirzepatide with dulaglutide in patients with diabetes and established cardiovascular disease.
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.
Continuing GLP-1/GIP agonists before upper endoscopy increased clinically significant residual gastric volume, but did not elevate adverse event risk. Clear liquids the day prior to the procedure may mitigate this risk.
Patients with type 2 diabetes and brain metastases who used GLP-1 receptor agonists showed a significant reduction in all-cause mortality. The use of these medications was associated with reduced neuroinflammation, preservation of the blood-brain barrier, and lowered oxidative stress and mitochondrial dysfunction.
A large cohort study found that fewer than 1 in 4 adults with overweight or obesity without diabetes remained on GLP-1RA treatment after 12 months. Treatment switching between GLP-1RA agents was common, reflecting active therapy management and the emergence of new formulations and weight management agents.
A low-cost digital intervention increased expectation to adopt health behaviors among adults using GLP-1RAs, with effects persisting for 2 weeks. The written microsteps intervention plus short video boosters may play a role in promoting sustained behavior change.
A novel plant-based approach uses lettuce chloroplasts to produce functional GLP-1 peptides, paving the way for more affordable and better-tolerated oral medications. This method bypasses hurdles such as manufacturing cost, delivery system, and side effects associated with conventional approaches.
A systematic review and meta-analysis found GLP-1 RAs produce significant weight loss across various subpopulations, including women who show improved outcomes compared to men. These findings have implications for clinical decision-making.
Researchers developed a novel method to immobilize proteins onto magnetic microbeads, allowing precise measurement of binding strength and efficient selection of target peptides. The technique achieved a 10,000-fold concentration in a single sorting step, significantly enhancing the efficiency of drug discovery research.
A team of scientists at the University of Sydney has discovered how three naturally occurring antibiotic compounds disrupt the ClpC1–ClpP1P2 complex, a vital protein degradation machine in Mycobacterium tuberculosis. This finding uncovers surprising complexity and provides valuable insight into designing more effective anti-TB treatments.
Researchers discovered that levetiracetam prevents the production of toxic amyloid-beta 42 peptides and plaques in neurons. Administering the drug to high-risk individuals may slow cognitive decline and prevent Alzheimer's symptoms if started early, possibly up to 20 years before symptoms appear.
A cohort study found combined GLP-1RA and progestin therapy reduces endometrial cancer risk in women with benign uterine pathology or endometrial hyperplasia. The study suggests potential benefits of this treatment approach for nonmalignant uterine diseases.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lowers risks of limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared to dipeptidyl peptidase-4 inhibitors in patients with diabetes. GLP-1 RAs are preferred for secondary prevention in this high-risk population.
After initiating GLP-1 receptor agonists, consumers showed a decrease in ultraprocessed foods and an increase in protein, while purchasing fewer calories, sugars, and saturated fats. These modest changes may have significant population-level effects given increasing GLP-1RA use.
A research team at Kumamoto University has developed a breakthrough drug-delivery platform using a small-intestine-permeable cyclic peptide, enabling efficient oral delivery of insulin. This approach achieves a pharmacological bioavailability of approximately 33–41% relative to subcutaneous injection.
A comparative effectiveness study found that SGLT2 inhibitors were associated with a lower risk of chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists. These findings suggest that SGLT2 inhibitor treatment may be an effective strategy for preventing kidney disease in individuals with type 2 diabetes.
Researchers at Cold Spring Harbor Laboratory have developed a new technique to improve mass spectrometry, enabling better drug target discovery and tumor analysis. The innovation increases sensitivity by breaking down scans into smaller bins, allowing for more accurate measurement of differences in concentration.
Using GLP-1 receptor agonists may lower the risk of vertebral compression fractures and related surgical interventions in people with type 2 diabetes. The study suggests that these medications have a bone-protective effect, offering benefits for patients.
A randomized clinical trial shows that semaglutide improves glycemic control and weight outcomes in individuals with schizophrenia. The study suggests using glucagon-like peptide-1 receptor agonists as an early intervention strategy to reduce cardiometabolic risk in this population.
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
A study found that women with obesity who stopped using GLP-1 receptor agonists experienced more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders. The research suggests that discontinuation of these medications may impact pregnancy outcomes.
Withdrawal of tirzepatide after 36-week treatment led to 25% or greater weight regain in most participants within a year, reversing initial cardiometabolic parameter improvements. Continued obesity treatment is crucial for sustained benefits.
A team of researchers from IOCB Prague introduces a novel method for labeling molecules with fluorescent dyes, surpassing existing approaches in precision and stability. This enables scientists to track labeled molecules over long periods with high reliability, expanding possibilities for research in biology, chemistry, and medicine.
Researchers identified two antimicrobial peptides that can kill various types of Salmonella and reduce its load in chickens. The study's findings suggest these peptides could improve food safety and public health by mitigating antibiotic resistance.
A cohort study found that GLP-1 receptor agonist use was associated with a reduced risk of developing nonexudative AMD, but not progression to exudative AMD in individuals with nonexudative AMD. This study may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
Researchers have discovered an enzyme called PapB that can create tight rings in therapeutic peptides, enabling the creation of stronger, longer-lasting versions of GLP-1 medications. This enzymatic method offers a simpler alternative to traditional chemical methods and could improve the stability and effectiveness of these drugs.
A new large language model, LassoESM, has been developed to predict lasso peptide properties, enabling the acceleration of rational design for biomedical applications. The model was trained on thousands of lasso peptide sequences and demonstrated accurate prediction of various properties.
A cohort study found that 40% of GLP-1RA orders were not filled, with lower rates among Non-Hispanic Black and Hispanic patients. These disparities may be attributed to differences in insurance coverage, GLP-1RA use, or cost thresholds.
The study reveals why some peptides are more effective and why certain bacterial cells are more vulnerable to membrane disruption. The findings provide a mathematical equation to identify optimal properties for efficacy, opening the door to designing novel compounds against antibiotic-resistant bacteria.
A new study from the Hebrew University of Jerusalem suggests that the stability of alpha amino acid backbones led to their selection as the foundation for proteins. The research proposes an assembly-driven model for the origins of life, offering fresh insight into how chemistry shaped biology.
A binational study found nearly 6 in 10 US adults and 3 in 10 Japanese adults discontinued semaglutide within 12 months of treatment. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates, highlighting the need for alternative treatments.
Prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal, leading to substantial out-of-pocket costs. Out-of-pocket costs for GLP-1RAs rose significantly from 2020 to 2025, affecting many high-cost drugs.
Metabolic bariatric surgery shows promise as a cost-effective weight loss option for class II and III obesity patients. The study found bariatric surgery resulted in greater weight loss compared to GLP-1 receptor agonists.
Researchers developed a novel biomaterial called elastin domain-derived protein (EDDP) that overcomes natural elastin limitations. EDDP promotes cell adhesion and growth, aiding tissue regeneration in damaged tissues like heart valves, blood vessels, or torn ligaments.
A systematic review and meta-analysis of 18 trials found GLP-1 RAs significantly improved glycemic and weight outcomes in children and adolescents with type 2 diabetes or obesity. However, gastrointestinal adverse effects warrant attention in long-term management.
Researchers found genetic peptides called alpha-defensins that shape gut bacteria, producing healthier microbiomes and reducing insulin resistance. This discovery suggests personalized treatments can be tailored to individual genes, offering new hope for addressing chronic diseases like obesity and diabetes.
A cohort study found GLP-1 RAs offer body mass index-dependent cardiovascular benefits and consistent kidney protection for type 2 diabetes patients. The study suggests BMI stratification is crucial for guiding treatment decisions.
Researchers at Penn Engineering introduced AMP-Diffusion, a generative AI tool that designed tens of thousands of new antimicrobial peptides with bacteria-killing potential. The most potent AMPs performed as well as FDA-approved drugs without detectable adverse effects.
Researchers at UCL successfully chemically linked amino acids to RNA under conditions that could have occurred on early Earth, a significant step towards understanding the origin of protein synthesis. The study demonstrates how RNA might have first come to control protein synthesis.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Researchers have discovered that combining antimicrobial peptides from bees and frogs can prevent bacteria from mutating quickly, making them a promising alternative to traditional antibiotics. This finding could lead to safer disease control in livestock and agricultural settings.
Cohort study finds GLP-1 receptor agonist use associated with modestly increased risk of incident diabetic retinopathy; however, those with preexisting DR experience fewer sight-threatening complications. Regular screening and monitoring recommended for all T2D patients on GLP-1 RAs.
A study found that semaglutide and liraglutide use are associated with a higher risk of nonarteritic anterior ischemic optic neuropathy in older patients with type 2 diabetes. The GLP-1 receptor agonists showed varying levels of risk, with liraglutide posing the greatest threat.
Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.
The Insilico Medicine recent summer updates webinar introduced new features and functional updates to the company's generative AI platform, including Generative Biologics, Chemistry42, PandaOmics, DORA, and PreciousGPT. These updates aim to accelerate drug discovery and advance life sciences research.
Researchers at the University of Ottawa have made a breakthrough in developing nanoparticles that not only deliver drugs but also contribute to treatment. Their proof-of-concept study shows that particles can be armed with therapeutic potential, revolutionizing the field of nanomedicine.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
Researchers mapped the frequencies used by Staphylococcus bacteria to communicate, identifying a signal from another species as potent against MRSA. This alternative technique weakens bacterial ability to coordinate attacks on hosts without killing them.
A cohort study found that GLP-1RAs like semaglutide and tirzepatide lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. The findings suggest potential neuroprotective benefits beyond glycemic control.
The article provides practical strategies for managing symptoms in patients receiving GLP-1 RAs, focusing on diet and physical activity interventions to support muscle and nutrient preservation. Lifestyle factors remain crucial in GLP-1 RA treatment for effective weight management.
A new study found significant reductions in medication use, symptoms, and procedural interventions with GLP-1 receptor agonist therapy for idiopathic intracranial hypertension. Further prospective studies are needed to confirm these findings.
A research team led by Professor Joongoo Lee successfully expanded ribosome range to produce ring-shaped backbones in proteins. This breakthrough could open doors to novel therapeutics and advanced biomaterials.
The use of GLP-1 receptor agonists among diabetes patients is associated with a higher risk of developing incident neovascular age-related macular degeneration. Further research is needed to understand the underlying mechanisms and trade-offs between benefits and risks.
GLP1-RA treatment is associated with improvements in quality of life, restrained eating, and emotional eating behavior. The treatment also provides reassurance regarding its psychiatric safety profile.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
The study estimates that expanded Medicare coverage for GLP-1RAs would increase access to these treatments and reduce obesity-related comorbidities. However, this would come with substantial costs over a decade, projected at $8 billion, highlighting the need for further price reductions and cost-saving strategies.
Two previously unknown ribosome-arresting peptides (RAPs), PepNL and NanCL, were identified in E. coli, inducing translation arrest through a unique mini-hairpin conformation in the exit tunnel of the ribosome. This discovery provides valuable insights into deciphering the hidden genetic codes within polypeptide sequences.